WallStreetZenWallStreetZen

NASDAQ: HOWL
Werewolf Therapeutics Inc Stock Ownership - Who owns Werewolf Therapeutics?

Insider buying vs selling

Have Werewolf Therapeutics Inc insiders been buying or selling?
No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when HOWL insiders and whales buy or sell their stock.

HOWL Shareholders

What type of owners hold Werewolf Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Ansbert Gadicke15.61%6,672,183$42.97MInsider
Ra Capital Management LP14.38%6,144,881$39.57MInstitution
Mpm Asset Management LLC10.02%4,284,172$27.59MInstitution
Luke Evnin10.02%4,284,172$27.59MInsider
Pfm Health Sciences LP8.12%3,468,177$22.34MInstitution
Mpm Bioventures 2014 LP7.46%3,187,998$20.53MInsider
Adage Capital Partners GP LLC7.10%3,034,255$19.54MInstitution
James E. Flynn5.97%2,552,787$16.44MInsider
Mpm Bioimpact LLC5.59%2,388,011$15.38MInstitution
Bank Of America Corp4.90%2,096,081$13.50MInstitution

1 of 3

HOWL vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
HOWL48.08%51.92%
ENTA58.46%41.54%Net SellingNet Selling
GLUE24.82%75.18%
INZY54.64%45.36%Net BuyingNet Selling
RAPT66.33%33.67%Net Selling

Werewolf Therapeutics Stock Ownership FAQ

Who owns Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ: HOWL) is owned by 64.74% institutional shareholders, 69.91% Werewolf Therapeutics insiders, and 0.00% retail investors. Ansbert Gadicke is the largest individual Werewolf Therapeutics shareholder, owning 6.67M shares representing 15.61% of the company. Ansbert Gadicke's Werewolf Therapeutics shares are currently valued at $42.64M.

If you're new to stock investing, here's how to buy Werewolf Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.